Press Releases

Mettler-Toledo Product Inspection has unveiled the new X3 Series of bulk flow x-ray inspection systems, designed to deliver class-leading physical contamination detection, precision waste reduction and simplified operation. Consisting of the X13 and X53 models, the design of the X3 Series for bulk inspection is developed from the acclaimed X2 family, with commonised parts. It offers hygienic design, s

Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications. Under the terms of the agreement, Pfizer will gain global rights to access Nona's proprietary HCAb platform to generate fully human heavy chain-only antibodies.

SCIEX, a global leader in life science analytical technologies, announces the localization of its X500R QTOF system, ZenoTOF 7600 system, and ZenoTOF 7600+ system in China. This strategic advancement underscores the company’s continued commitment to accelerate localization efforts for its products in China, building upon the successful localization of the entire current triple quadrupole portfolio in Suzhou between 2023 and 2025. The introduction of these additional high-resol

Longeveron Inc. a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering administration of the Company’s proprietary Mesenchymal Stem Cells (MSCs) for the treatment of patients with symptoms of aging-related frailty. U.S. Patent No. 12,465,620, entitled “Method of Treating Aging

Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, today announced a partnership for process transfer and cGMP manufacturing of HGI627, a novel therapy  targeting pediatric liver cancer (hepatoblastoma). Humane Genomics uses its proprietary synthetic RNA virus platform to rapidly design and engineer RNA viruses with precise anti-cancer capabilities. Throug

Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is based on a strong mutual consensus: Sanyou Bio possesses profound expertise in innovative biopharmaceutical discovery and development, while Yugong Bio holds core advantages in enzyme engineering and large-scale production. This powerf

Revvity, Inc. today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The trans

Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols™ ExTend Cap AU, an RNA polymerase engineered to significantly improve manufacturing of self-amplifying mRNA vaccines and therapeutics. ExTend Cap AU enables high-yield, fully capped self-amplifying mRNA with less capping reagent, template DNA and RNA polymerase. Built specifically for AU cap analogs, dsRNA reduction combined

Today it was announced that Novo Nordisk has agreed with the U.S. Administration to lower drug prices beginning in 2026 and expand patient access and affordability for semaglutide medicines, including Wegovy® and Ozempic®, in U.S. Medicare Part D and Medicaid and in direct-to-patient cash channel. Medicare Part D coverage for anti-obesity medicines will be enabled through a pilot program designed to cover a majority of Part D beneficiaries. In addition, Novo Nordisk is expected to rec

Eli Lilly and Company today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines. In 2020, Lilly partnered with the Trump Administration on a pilot program that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improv